developed and pilot tested the materials, reviewed and analyzed the data, provided written discussions for feedback to participants, and developed a proposed assessment system to allow for eventual grading of laboratory performance. During the first 3 years, the survey was designed to utilize only "dry" challenges; electropherograms were distributed to participants for analysis and interpretation of sequence variants. This is in contrast to the current "wet" European sequencing program, which provides DNA that participants sequence and then interpret (http://www.emqn.org/emqn/schemes). A dry survey is a simpler approach, could be initiated more readily, and would be less expensive for laboratories to join. The addition of wet challenges could be phased in later. Although the committee is supportive of methods-based PT, if a disease-specific PT program is available for a gene that the laboratory sequences, participation in that disease-specific survey would still be required.
Here, we present the initial 3 years of experience providing the first molecular methods-based PT program based in the United States. International participants are also welcome. This is one of a series of publications from the CAP/ACMG Biochemical and Molecular Genetics Resource Committee, which presents and interprets PT data. Disease-specific reports have already been published for Huntington disease 7 and fragile X, 8 with other manuscripts in preparation. So far, these reports have provided evidence that US clinical laboratories are performing well.
MAteriALs And MetHods contents of the sec survey
The SEC survey includes two distributions of three challenges each year. Information about the introduction of this survey was included in the CAP Surveys Catalog and on the CAP homepage 9 and was available through the CAP exhibitors present at relevant annual scientific and professional meetings. Participants were provided with a CD that included three challenge sequence data files (ABI files, forward and reverse sequences for each amplicon); three wild-type sequence data files (ABI files, forward and reverse sequences for each amplicon); the gene name, genomic reference sequence (RefSeq) number (NG_nnnnn), and the coding RefSeq number (NM_ nnnnnn); a translation of the sequence (Word); a Mutation http://www.cftr2.org/). All data were derived from Sanger sequencing in a reference clinical laboratory using an ABI3130 instrument and checked for acceptable quality scores before inclusion in the survey. The product was blindly pilot tested by committee members before distribution. For consistency, participants were asked to use only the coding DNA position (not the genomic position) for nucleotide changes and use standard Human Genome Variation Society nomenclature. The gene name or reference sequence number in the variant description was not to be included. Laboratories were also asked to identify all variants relative to the provided reference sequence, not just those expected to be pathogenic. If more than one variant was identified, participants were instructed to report each change in the order of the gene from 5′ to 3′. Finally, laboratories were to indicate whether each variant was heterozygous or homozygous and to interpret each variant as pathogenic, benign, or of unknown clinical significance, using the ACMG Interpretation of Sequence Variants report as a guideline. 19 Laboratories were given 3 weeks to analyze and report their findings.
supplemental questions
Each SEC survey also contained supplemental questions intended to provide insight into the experience, current needs, and future directions of participants. Questions included what changes in technology were occurring, current methods, numbers of samples sequenced per year, where the laboratory was located, and information regarding methods employed to assess functional significant and potential pathogenicity. A summary of the responses were included in the participant summary report at least once each year.
Analysis of results
Participants assess each identified variant for zygosity (heterozygous or homozygous) and provide a free-text response for nucleotide and protein description. The fourth assessment component is a determination of pathogenicity (benign, pathogenic, or of unknown clinical significance). The initial summary of results is provided to designated committee members, listing their responses. The participant's identity is not revealed. A committee member performs the primary review and provides an analysis of results, placing each response into an acceptable/ unacceptable category. A draft discussion summarizes the findings and helps laboratories improve practice. Additional committee members review the analyses and discussion and make comments before the final version distributed to participants.
Potential assessment of the sec participants
Each challenge so far has contained at least one variant, and each of these variants requires responses to the four components (zygosity, nucleotide change, protein change, and interpretation). For each distribution (three challenges), this provides a matrix of 12 responses per survey. If additional variants are present, the matrix expands in multiples of four. Each of the responses can be assessed, if an 80% consensus is reached. One approach to assessment would be to give each acceptable response one point; no points if the response is either unacceptable or missing. The sum could then be used as an overall assessment. Having a score of 10 or higher out of 12 would be acceptable, with 9 or below being unacceptable. If a participant consistently misses one component, then a letter with specific recommendations for improvement in performance could be sent.
Original research article resuLts characteristics of sec survey participants Table 1 shows the results of the 2012 questionnaire regarding characteristics of the survey participants, stratified by whether the laboratory was located within the United States or was international. Only clinical laboratories were included (four research laboratories were excluded). Responses were from the 2012A survey except for two US participants for whom data from 2011 was used (data was not reported in 2012). Eleven US and 17 international participants never completed the questionnaire.
Nearly all of the participants currently rely on Sanger sequencing, but several report current use of next-generation sequencing platforms. Nearly two-thirds of the participants plan on incorporating next-generation sequencing in the coming year (33 of 46 in the United States and 13 of 26 international, based on a 2011B query). The numbers of samples processed ranged broadly. Eighteen participants (20%) processed <100 patient samples per year, whereas 23 (26%) processed >2,000. An estimated 62,000 gene-sequencing tests were performed by laboratories in the United States each year. Only one US laboratory, but five international participants, offered testing directly to consumers. The majority of participants (72%) offered sequencing for ≤50 genes, and 33 (37%) reported being the sole laboratory providing sequencing for ≥1 genes. There was a significantly higher proportion of US laboratories that participated in external PT for every gene sequenced (64 vs. 32%, two-tailed exact P = 0.005). Nearly all (93%) participants used software to facilitate sequence analysis, and most used three common programs. Table 1 provides a summary of the methods that are used to assess function of missense changes and pathogenicity of variants in noncoding regions. Most laboratories use predictive algorithms that are listed in the table footnotes as well as family studies, if appropriate. Fewer laboratories confirm splice variants, and none perform functional analysis to confirm variants. Finally, more than 90% of US laboratories reported variants using ACMG-recommended guidelines, 19 as compared with 76% of international laboratories. Table 2 shows information regarding the number of participants, the gene challenge, and the types of sequence variant challenged over the 3 years. There is steady growth in the number of participants, increasing from 53 in the first distribution in 2010 to 90 in the last distribution in 2012. Six different genes have been included, including FANCA and FANCC (Fanconi anemia complementation group A and C, respectively), responsible for Fanconi anemia (an ultra-rare disorder), and CFTR (cystic fibrosis transmembrane conductance regulator), a commonly sequenced gene responsible for cystic fibrosis. All but two of the variants challenged so far have been pathogenic. The two benign variants occurred as a second variant (2011A-01V2 and 2012A-01V2). Not all responses for nucleotide and protein nomenclature that were considered acceptable were exactly the same as the anticipated response listed in Table 3 . Many of the minor inconsistencies involved capitalization, abbreviations of amino acids, and incorrect punctuation. For example, the anticipated nucleotide response for 2011B-05 was "c.1366delG, " but "C.1366 DELG" was considered acceptable. Incorrect responses for that challenge included "c.13654delG" and "C.1783DELG. " For that same challenge, the intended response for the protein nomenclature was "p.Val456CysfsX9, " but "p.V456Cfs9, " "p.Val456Cys*fs, " "p.VAL 456CYSFSX9, " and "p.V456CfsX9" were considered acceptable. One incorrect response reported for this challenge was "P.E455G fs. " Figure 1 shows component-specific responses by participant for all 67 US laboratories providing responses for at least one distribution, sorted by the numbers of samples tested per year. The last seven rows include participants that never reported this result. Each box indicates a potential response to a challenge, component by component (the letters Z, N, P, and I indicate the four components (zygosity, nucleotide change, protein change, and interpretation, respectively)). Open boxes indicate no response (either because that component was not reported or because it was not challenged). Gray squares indicate acceptable responses, whereas black squares indicate unacceptable responses. Reading horizontally provides an individual laboratory's results, whereas reading vertically indicates overall performance for that component of the challenge. The sample labels (e.g., 2010B-04) can be linked to Table 2 to identify the gene and variant challenged. Among the US laboratories, 25 (37%) had all acceptable responses, whereas another 16 (24%) had rates of ≥95%. Another 21 (31%) had rates of 90-94.9%, but five (8%) had rates <90%. Overall, 2,989 of 3,104 responses (96.3%) were deemed acceptable. If the four components that did not reach consensus were removed, the rate increases to 97.4% (2,850/2,927). Figure 2 shows the same data for the 50 international participants (North/South America-excluding the United States (22 participants), Asia (18) , the Mideast (6), and Europe (4)). Of these, 14 participants (28%) had all acceptable responses and 16 (29%) had rates of ≥95%. Ten (20%) were between 90 and Original research article 94.9% and 10 (20%) had rates <90%. Overall, 1,794 of 1,895 assessed responses (94.7%) were deemed acceptable. If the four components that did not reach consensus were removed, this rate increases to 95.5% (1,788/1,873).
survey challenges and responses

retrospective assessment of performance
The proposed assessment scheme was retrospectively applied to the 3 years' worth of data. Because only two components were challenged in 2010A, and there were initial difficulties with some participants in understanding the survey, these challenges are not included. Participant results from the five remaining distributions (2010B through 2012B) were assessed. If no responses were present for a given challenge (or variant within a challenge), it was assumed that the laboratory skipped the challenge. In the future, not reporting a variant may be considered unacceptable performance. Acceptable assessments were obtained for 35 of 36, 44 of 46, 41 of 42, 55 of 55, and 56 of 56 US participants, respectively, for an overall rate of 98.3% (235/239; 95% confidence interval: 95.8-99.5%). Acceptable assessments were obtained for 20 of 21, 22 of 28, 26 of 32, 32 of 37, and 34 of 35 international participants, respectively, for an overall rate of 88.9% (136/153; 95% confidence interval: 82.8-93.4%). These rates are significantly different (exact two-tailed P < 0.001).
discussion
The methods-based SEC survey currently focuses on Sanger sequencing. During the first 3 years, the survey was based only on analysis and interpretation of provided sequence data. It was, at least in part, developed in response to the recommendation that rare disorder-testing laboratories need an external PT program to help ensure quality. 4 The results show that the vast majority of laboratories offering sequencing for rare diseases are able to accurately identify, name, and interpret sequence variants. In the United States, 98.3% of gradable assessments would have been considered acceptable. These findings provide quantitative evidence that supports the high quality of sequencing tests for rare disorders performed in US clinical laboratories.
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